



**Press Release  
For Immediate Release  
January 6, 2017**

**Parkinson's Institute and Clinical Center partners with CENTOGENE to characterize Parkinson's patients with targeted gene panel**

**Rostock/Berlin, Germany and Sunnyvale, California, USA:** For the first time, ever, the Parkinson's Institute and Clinical Center and CENTOGENE have entered into a collaboration aimed at genetic screening of a large cohort of Parkinson's patients in the US. Now, individual patients will be screened using a large customized panel carefully selected to identify pathophysiological relevant genetic variants for the development and treatment of Parkinson's disease.

"This genetic screening will not only help provide actionable decisions for treating physicians but also the knowledge obtained will provide further insights for pharmaceutical and biotech companies conducting research in novel treatments for this debilitating disease," says Dr. Carolee Barlow, CEO, Parkinson's Institute and Clinical Center.

The Parkinson's Institute is excited about collaborating with CENTOGENE, because this collaboration will allow genetic samples to be genetically characterized with highest standards at the CAP/CLIA certified CENTOGENE labs in Germany and genetic reports will be returned to patient's physicians.

"We are pleased to work with CENTOGENE, a leading international company in determining the genetic drivers for Parkinson's disease," stated Dr. Barlow. "CENTOGENE's expertise in genetic characterization will help us to apply the right treatment for patients now and offer them hope for the future."

Dr. Arndt Rolfs, CEO of CENTOGENE, Professor for Neurology and Movement Disorder expert said, "We are thrilled to join forces to advance the important work done by the Parkinson's Institute and look forward to working with them as well as the pharmaceutical industry to further develop novel treatments for patients."

**Contact: Doreen Niemann, CENTOGENE**  
**E-mail: [doreen.niemann@centogene.com](mailto:doreen.niemann@centogene.com)**  
**Phone: +49 381 203652 181**

**Chris Di Salvo, Parkinson's Institute**  
**E-mail: [profef@aol.com](mailto:profef@aol.com)**  
**Mobile: +1 408-506-045**

### **About CENTOGENE:**

CENTOGENE is a worldwide leader in the field of genetic diagnostics for rare hereditary diseases - with the largest test portfolio worldwide. Testing samples from over 110 different countries allows CENTOGENE a unique insight into epidemiological basis of hereditary disorders, which is crucial in the medical result interpretation process. The company is strictly focusing on offering quality molecular genetic diagnostics, underlined by its multiple international accreditations (ISO, CAP, CLIA). CENTOGENE's in depth medical expertise is supported by the application of cutting-edge technologies including next generation sequencing, whole exome sequencing (CentoXome<sup>®</sup>), whole genome sequencing (CentoGenome<sup>®</sup>) and innovative biomarkers for selected diseases. CENTOGENE has developed a comprehensive mutation database (CentoMD<sup>®</sup>) that is pivotal to offering high quality diagnostic reporting and medical interpretation; thoroughly interpret each patient's sequence data. In addition to diagnostic services for individual patients, CENTOGENE is also a pivotal partner for multiple renowned industrials worldwide. CENTOGENE has affiliations in Germany, India, Canada, Austria, and the United Arab Emirates.

For more information, please visit [www.centogene.com](http://www.centogene.com) and [info.centomd.com](http://info.centomd.com)

### **About the Parkinson's Institute and Clinical Center:**

The mission of The Parkinson's Institute (The PI) is to provide comprehensive patient care, while discovering new treatment options to improve the quality of life for all Parkinson's disease (PD) patients. As America's only independent non-profit organization combining research and patient care for PD under one roof, we are committed to changing the landscape of movement disorder treatment and research. Since its founding, The PI has helped thousands of PD patients better manage their disease, developed new treatments for PD, and published groundbreaking research aimed to close the gap between science and practical care. By focusing on all three avenues of PD - cause, care and cure – the PI is a powerful force in PD research.

For more information, please visit [www.theipi.org](http://www.theipi.org)

**Contact:** Doreen Niemann, CENTOGENE  
**E-mail:** [doreen.niemann@centogene.com](mailto:doreen.niemann@centogene.com)  
**Phone:** +49 381 203652 181

**Chris Di Salvo, Parkinson's Institute**  
**E-mail:** [profef@com](mailto:profef@com)  
**Mobile:** +1 408-506-045